Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 27, 2016

Primary Completion Date

June 3, 2017

Study Completion Date

July 20, 2017

Conditions
Breast CancerLymphomaPain
Interventions
DRUG

Pregabalin

During the first chemotherapy cycle, the patient will receive pregabalin 75mg (1 capsule) BID x 4 days before pegfilgrastim 6mg subcutaneous (SC) x1; then pregabalin 150mg (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive placebo in the same dosing scheme.

DRUG

Placebo

During the first chemotherapy cycle, the patient will receive placebo (1 capsule) BID x 4 days before pegfilgrastim 6mg SC x1; then placebo (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive pregabalin in the same dosing scheme.

Trial Locations (1)

27514

North Carolina Cancer Hospital, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER